Racial and Ethnic Diversity in FDA Regulated Clinical Trials
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the…
My Profile
Member Center
Policy
Top Priorities
On behalf of our members, AdvaMed works on countless fronts to ensure patients have timely access to life-changing technologies. Find out more about our top policy issues.
Your Featured Resources
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the…
PFAS in Medtech
Per- and polyfluoroalkyl substances, known as PFAS, are a broad class of over 12,000 substances that are found in a variety of consumer, commercial and industrial products, including medical devices…
Phase III: Disparities in Access to Selected Advanced Medical Procedures in the Medicare Population
The final report of a three-part series investigates the prevalence of racial and ethnic disparities in the use of in the use of advanced interventions in the Medicare program.
Phase II: Literature Review: Racial Disparities in Use of Selected Medical Technologies
The second of a three-phase research series examines the difference in access to certain advanced interventions, including a range of surgical, medical and technological interventions.
Phase I: Disparities in Access to Advanced Medical Procedures in the Medicare Population
Racial and ethnic healthcare disparities in access to advanced interventions have persisted in the U.S. medical system. The first of a three-phase research series examines the difference in access to…
Additional Resources
Racial and Ethnic Diversity in FDA Regulated Clinical Trials
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the…
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the…
PFAS in Medtech
Per- and polyfluoroalkyl substances, known as PFAS, are a broad class of over 12,000 substances that are found in a variety of consumer, commercial and industrial products, including medical devices…
Phase III: Disparities in Access to Selected Advanced Medical Procedures in the Medicare Population
The final report of a three-part series investigates the prevalence of racial and ethnic disparities in the use of in the use of advanced interventions in the Medicare program.
Discover More Resources
AdvaMed members have access to our full library of industry resources.
You are not logged in to the AdvaMed Hub.
AdvaMed, CTA Host Congressional Briefing on Remote Patient Monitoring
Today, AdvaMed, the Medtech Association, and Consumer Technology Association (CTA)® hosted a Congressional Digital Health Caucus briefing on remote patient monitoring (RPM) in coordination with Caucus co-chairs Rep. Troy Balderson…
AdvaMed Responds to Congressional RFI on AI in Health Care
This week, AdvaMed, the Medtech Association, responded to a request for information from Congressman Ami Bera regarding the use of artificial intelligence (AI) in health care.
Your Travel Planning Guide for The MedTech Conference
Greetings from AdvaMed, the host of the 2024 MedTech Conference in Toronto, Canada. Understanding how valuable your time and investment are, we’ll help you plan for critical business development at…
Integrity Orthopaedics Announces Closure Of Series B Financing
Integrity Orthopaedics, Inc., a company pioneering next generation solutions for soft tissue repair, has successfully closed on a Series B financing of $20.6 million.
AdvaMed Statement on the Release of FDA Rule on Laboratory-Developed Tests
Today, AdvaMed, the Medtech Association, released the following statements from President and CEO Scott Whitaker and Zach Rothstein, Executive Director of AdvaMedDx, on FDA’s final rule for Laboratory Developed Tests (LDTs):
New Episode of Medtech POV Podcast: Nanowear CEO Venk Varadan Details Medtech Startup Journey, Regulatory Pathway, and Payment Hurdles Facing Industry
The newest episode of Medtech POV with Scott Whitaker, out today on all podcast streaming platforms, highlights Venk Varadan’s journey as a medtech entrepreneur. Varadan, CEO and co-founder of Nanowear,…
AdvaMed Urges Senate Leader to Prioritize R&D Tax Credit in Any Tax Package
This week, in a letter to Senate Majority Leader Chuck Schumer, AdvaMed President and CEO Scott Whitaker underscored the critical importance of passing a tax provision that allows small businesses…
AdvaMed Statement on FDA-USAID India Regulatory Session
AdvaMed, the Medtech Association, released the following statement thanking the FDA Center for Radiological Health (CDRH) for recently hosting an event in New Delhi to discuss regulatory policies and best practices for ensuring…
Nectero Medical Announces Completion of $96M Series D Financing
Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing was led by Norwest Venture…
AdvaMed to CMS: “1,138 Days Without Breakthrough Coverage is Harming Seniors”
AdvaMed, the Medtech Association, unveiled a timer on the organization’s website to track the number of days since the Centers for Medicare and Medicaid Services (CMS) ended the coverage pathway…
Membership Newsletter
We are pleased to provide AdvaMed members with the Membership Newsletter, a monthly publication designed to communicate relevant news, resources, events and policy updates.